000309984 001__ 309984
000309984 005__ 20260220155857.0
000309984 0247_ $$2doi$$a10.1158/2767-9764.CRC-25-0599
000309984 0247_ $$2pmid$$apmid:41566838
000309984 037__ $$aDKFZ-2026-00410
000309984 041__ $$aEnglish
000309984 082__ $$a610
000309984 1001_ $$0P:(DE-He78)72f465234033973e5e61125cf51b50b0$$aTraichel, Jasmin$$b0$$udkfz
000309984 245__ $$aNovel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.
000309984 260__ $$aPhiladelphia, Pa.$$bAmerican Association for Cancer Research$$c2026
000309984 3367_ $$2DRIVER$$aarticle
000309984 3367_ $$2DataCite$$aOutput Types/Journal article
000309984 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771599522_3240618
000309984 3367_ $$2BibTeX$$aARTICLE
000309984 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309984 3367_ $$00$$2EndNote$$aJournal Article
000309984 520__ $$aCombining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.
000309984 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309984 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309984 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProto-Oncogene Proteins B-raf
000309984 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aBRAF protein, human
000309984 650_7 $$2NLM Chemicals$$aProtein Kinase Inhibitors
000309984 650_2 $$2MeSH$$aAnimals
000309984 650_2 $$2MeSH$$aColorectal Neoplasms: genetics
000309984 650_2 $$2MeSH$$aColorectal Neoplasms: pathology
000309984 650_2 $$2MeSH$$aColorectal Neoplasms: drug therapy
000309984 650_2 $$2MeSH$$aProto-Oncogene Proteins B-raf: genetics
000309984 650_2 $$2MeSH$$aProto-Oncogene Proteins B-raf: antagonists & inhibitors
000309984 650_2 $$2MeSH$$aMice
000309984 650_2 $$2MeSH$$aHumans
000309984 650_2 $$2MeSH$$aCell Line, Tumor
000309984 650_2 $$2MeSH$$aMutation
000309984 650_2 $$2MeSH$$aProtein Kinase Inhibitors: pharmacology
000309984 650_2 $$2MeSH$$aDrug Resistance, Neoplasm
000309984 7001_ $$00009-0008-8611-3415$$aMetzger, Ariane$$b1
000309984 7001_ $$00009-0009-8381-415X$$aWalz, Maria$$b2
000309984 7001_ $$00000-0002-4437-2194$$aFeuerstein, Reinhild$$b3
000309984 7001_ $$00000-0003-3228-053X$$aWohlfeil, Nadine$$b4
000309984 7001_ $$aMetzger, Patrick$$b5
000309984 7001_ $$00000-0001-5745-2161$$aMarx, Lisa$$b6
000309984 7001_ $$00000-0002-7639-9332$$aAsdih, Célia$$b7
000309984 7001_ $$00009-0009-0584-7108$$aLindenthal, Agnes$$b8
000309984 7001_ $$00009-0008-1541-1482$$aSeger, Alina$$b9
000309984 7001_ $$00009-0007-9776-817X$$aSchrimpf, Jule$$b10
000309984 7001_ $$aNardella, Luigi L$$b11
000309984 7001_ $$aKowar, Silke$$b12
000309984 7001_ $$00000-0003-2735-5509$$aFrew, Ian J$$b13
000309984 7001_ $$00000-0002-6827-8178$$aHalbach, Sebastian$$b14
000309984 7001_ $$00000-0001-8131-7605$$aKesselring, Rebecca$$b15
000309984 7001_ $$00000-0002-3670-0602$$aBoerries, Melanie$$b16
000309984 7001_ $$00000-0003-1368-2832$$aGriffin, Ricarda$$b17
000309984 7001_ $$0P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9$$aBrummer, Tilman$$b18$$udkfz
000309984 773__ $$0PERI:(DE-600)3098144-X$$a10.1158/2767-9764.CRC-25-0599$$gVol. 6, no. 2, p. 320 - 339$$n2$$p320 - 339$$tCancer research communications$$v6$$x2767-9764$$y2026
000309984 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)72f465234033973e5e61125cf51b50b0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000309984 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-2735-5509$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000309984 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-6827-8178$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000309984 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8131-7605$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000309984 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-3670-0602$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000309984 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000309984 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309984 9141_ $$y2026
000309984 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-12-06T11:12:23Z
000309984 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-12-06T11:12:23Z
000309984 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-12-06T11:12:23Z
000309984 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-12-06T11:12:23Z
000309984 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-11
000309984 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-11
000309984 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK Koordinierungsstelle Freiburg$$x0
000309984 980__ $$ajournal
000309984 980__ $$aVDB
000309984 980__ $$aI:(DE-He78)FR01-20160331
000309984 980__ $$aUNRESTRICTED